Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Diabetologia
Published in: Diabetologia 5/2016

01-05-2016 | Commentary

Bariatric surgery: traversing the CROSSROADS into mainstream diabetes care

Authors: Karl J. Neff, Carel W. le Roux

Published in: Diabetologia | Issue 5/2016

Login to get access

Excerpt

Over the last decade, bariatric surgery has come to be recognised for its effects beyond weight loss. The long-term results of the Swedish Obese Subjects (SOS) study have shown an effect on disease risk, morbidity and mortality [1]. Importantly, there are also clear effects on both preventing the onset of diabetes in obese cohorts, and in producing substantial improvements in glucose homeostasis in those with pre-operative diabetes. This considerable effect facilitates the achievement of treatment targets by diabetic individuals with less medication [2‐5]. …
Literature
1.
Sjostrom L, Peltonen M, Jacobson P et al (2012) Bariatric surgery and long-term cardiovascular events. JAMA 307:56–65CrossRefPubMed
2.
Mingrone G, Panunzi S, De Gaetano A et al (2015) Bariatric-metabolic surgery versus conventional medical treatment in obese patients with type 2 diabetes: 5 year follow-up of an open-label, single-centre, randomised controlled trial. Lancet 386:964–973CrossRefPubMed
3.
Schauer PR, Bhatt DL, Kirwan JP et al (2014) Bariatric surgery versus intensive medical therapy for diabetes—3-year outcomes. N Engl J Med 370:2002–2013CrossRefPubMed
4.
Miras AD, le Roux CW (2014) Metabolic surgery: shifting the focus from glycaemia and weight to end-organ health. Lancet Diabetes Endocrinol 2:141–151CrossRefPubMed
5.
Dixon JB, le Roux CW, Rubino F, Zimmet P (2012) Bariatric surgery for type 2 diabetes. Lancet 379:2300–2311CrossRefPubMed
6.
Cummings DE, Arterburn DE, Westbrook EO et al (2016) Gastric bypass surgery vs intensive lifestyle and medical intervention for type 2 diabetes: the CROSSROADS randomised controlled trial. Diabetologia DOI:
7.
Miras AD, Chuah LL, Khalil N et al (2015) Type 2 diabetes mellitus and microvascular complications 1 year after Roux-en-Y gastric bypass: a case-control study. Diabetologia 58:1443–1447CrossRefPubMedPubMedCentral
8.
Carlsson LM, Romeo S, Jacobson P et al (2015) The incidence of albuminuria after bariatric surgery and usual care in Swedish Obese Subjects (SOS): a prospective controlled intervention trial. Int J Obes (Lond) 39:169–175
9.
Fenske WK, Dubb S, Bueter M et al (2013) Effect of bariatric surgery-induced weight loss on renal and systemic inflammation and blood pressure: a 12-month prospective study. Surg Obes Relat Dis 9:559–568CrossRefPubMed
Metadata
Title
Bariatric surgery: traversing the CROSSROADS into mainstream diabetes care
Authors
Karl J. Neff
Carel W. le Roux
Publication date
01-05-2016
Publisher
Springer Berlin Heidelberg
Published in
Diabetologia / Issue 5/2016
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-016-3928-1

Other articles of this Issue 5/2016

Diabetologia 5/2016 Go to the issue

Review

Improved glucose regulation in type 2 diabetic patients with DPP-4 inhibitors: focus on alpha and beta cell function and lipid metabolism

Article

Incidence of register-based diabetes 10 years after a stepwise diabetes screening programme: the ADDITION-Denmark study

MINI-Review

The role of leptin in diabetes: metabolic effects

Article

First-trimester multimarker prediction of gestational diabetes mellitus using targeted mass spectrometry

Article

Decoration of intramyocellular lipid droplets with PLIN5 modulates fasting-induced insulin resistance and lipotoxicity in humans

Research Letter

Insomnia does not mediate or modify the association between MTNR1B risk variant rs10830963 and glucose levels
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits